AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32456525 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (EZE) in monotherapy (3 months)
Number of subjects: 96
Study 32456525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) + Nutraceutical Compound (NC)
Number of subjects: 96
Study 32456525 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (EZE) in monotherapy
Number of subjects: 96
Study 32950246 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl dosing
Number of subjects: 50
Study 32950246 — intervention group
Group type: COMPARATOR
Intervention: Standard care (fentanyl dosing based on haemodynamics)
Number of subjects: 50
Study 32950246 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 35107612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramini-percutaneous nephrolithotomy (UMP)
Number of subjects: 150
Study 35107612 — intervention group
Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 150
Study 33894543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led web-based home asthma education program
Number of subjects: 112
Study 33894543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 32513424 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Number of subjects: 192
Study 32513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 192
Study 32513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 192
Study 32513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 192
Study 32513424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 36316694 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation of the inferior mesenteric artery (IMA)
Number of subjects: 314
Study 36316694 — intervention group
Group type: COMPARATOR
Intervention: Low ligation of the inferior mesenteric artery (IMA)
Number of subjects: 314
Study 34526307 — intervention group
Group type: EXPERIMENTAL
Intervention: H3 diet (n=61) - increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy
Number of subjects: 182
Study 34526307 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-L6 diet (n=61) - increase n‐3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy
Number of subjects: 182
Study 34526307 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n=60) - maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy
Number of subjects: 182
Study 32681688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 74
Study 32681688 — intervention group
Group type: COMPARATOR
Intervention: Intralesional vitamin D3
Number of subjects: 74
Study 34414486 — intervention group
Group type: EXPERIMENTAL
Intervention: Malerba osteotomy
Number of subjects: 34
Study 34414486 — intervention group
Group type: COMPARATOR
Intervention: Combined Evans/Medial Displacement Calcaneal Osteotomy (MDCO)
Number of subjects: 34
Study 34396513 — intervention group
Group type: EXPERIMENTAL
Intervention: PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Number of subjects: 60
Study 34153451 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblong tablet (2.5 × 6 mm)
Number of subjects: 280
Study 34153451 — intervention group
Group type: COMPARATOR
Intervention: Syrup (3 ml glucose syrup)
Number of subjects: 280
Study 34153451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-tablets (2 × 2 mm)
Number of subjects: 280
Study 33901109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplants from donors with infective endocarditis
Number of subjects: 42
Study 33901109 — intervention group
Group type: COMPARATOR
Intervention: Matched control transplants
Number of subjects: 42
Study 34618790 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic Lumbosacral Orthoses (iLSOs)
Number of subjects: 300
Study 34618790 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Lumbosacral Orthoses (eLSOs)
Number of subjects: 300
Study 34618790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LSO)
Number of subjects: 300
Study 36496367 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxgraft® (freeze‐dried, multiple donors)
Number of subjects: 60
Study 36496367 — intervention group
Group type: EXPERIMENTAL
Intervention: Puros® (solvent‐dehydrated, single donor)
Number of subjects: 60
Study 36496367 — intervention group
Group type: COMPARATOR
Intervention: Control group (autologous, 10 patients)
Number of subjects: 60
Study 36496367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (patients developing positive LTT at T2)
Number of subjects: 60
Study 36496367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (LTT positive T1‐T3)
Number of subjects: 60
Study 34389407 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT (combined modality therapy) with 20 Gy IF-RT after chemotherapy
Number of subjects: 1150
Study 34389407 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (without IF-RT)
Number of subjects: 1150
Study 34389407 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT (combined modality therapy)
Number of subjects: 1150
Study 32416978 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 620
Study 32416978 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 620
Study 34304301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides root extracts (n=82)
Number of subjects: 164
Study 34304301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=82)
Number of subjects: 164
Study 32551097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg doses every 8 hours)
Number of subjects: 40
Study 32551097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 32551097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 40
Study 32551097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32551097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and Placebo
Number of subjects: 40
Study 33112417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 21
Study 33112417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 36461035 — intervention group
Group type: EXPERIMENTAL
Intervention: Kami Guibi-tang (KGT)
Number of subjects: 84
Study 36461035 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 84
Study 33550930 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (PIT), n=88
Number of subjects: 164
Study 33550930 — intervention group
Group type: COMPARATOR
Intervention: Enhanced medical care (EMC), n=76
Number of subjects: 164
Study 35707180 — intervention group
Group type: EXPERIMENTAL
Intervention: Height ≥170 cm
Number of subjects: 4935
Study 35707180 — intervention group
Group type: COMPARATOR
Intervention: Height <160 cm
Number of subjects: 4935
Study 32065485 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine patches (CHG patches)
Number of subjects: 192
Study 32065485 — intervention group
Group type: COMPARATOR
Intervention: Standard transparent dressings
Number of subjects: 192
Study 34100788 — intervention group
Group type: EXPERIMENTAL
Intervention: MHJB training protocol (3 times per week for 6 weeks)
Number of subjects: 14
Study 34100788 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily workout without MHJB protocol)
Number of subjects: 14
Study 33361470 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (300 minutes per week at 50% to 60% of peak oxygen consumption)
Number of subjects: 0
Study 33361470 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36316682 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention comprising seven group sessions and a cooking class addressing healthier diet and increased physical activity
Number of subjects: 92
Study 36316682 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual with information to improve lifestyle habits on their own
Number of subjects: 92
Study 36316682 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 92
Study 36316682 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 92
Study 34740351 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal counselling intervention (five monthly counselling sessions plus usual care)
Number of subjects: 534
Study 34740351 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group)
Number of subjects: 534
Study 35270238 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill intervention
Number of subjects: 0
Study 35270238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34551779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (HbA1c ≥ 7%, n = 106)
Number of subjects: 201
Study 34551779 — intervention group
Group type: COMPARATOR
Intervention: Control group (HbA1c < 7%, n = 95)
Number of subjects: 201
Study 32958377 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIFS training
Number of subjects: 30
Study 32958377 — intervention group
Group type: COMPARATOR
Intervention: Care‐as‐Usual (CaU) training
Number of subjects: 30
Study 32493372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (IM) + Patient-Controlled Epidural Anesthesia (PCEA)
Number of subjects: 50
Study 32493372 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (IM)
Number of subjects: 50
Study 34895717 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiflow THRIVE™ at 70 L min‐1 oxygen
Number of subjects: 42
Study 34895717 — intervention group
Group type: COMPARATOR
Intervention: Nasal prong oxygen at 4 L min‐1
Number of subjects: 42
Study 34542058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mézières method (MM)
Number of subjects: 54
Study 34542058 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 54
Study 32035514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed-platinum
Number of subjects: 616
Study 32035514 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed-platinum
Number of subjects: 616
Study 35246228 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy (ten biweekly 90-min sessions)
Number of subjects: 159
Study 35246228 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 159
Study 35246228 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 159
Study 34508257 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic-band resistance training with vitamin D3 supplementation (ED)
Number of subjects: 40
Study 34508257 — intervention group
Group type: COMPARATOR
Intervention: Elastic-band resistance training with placebo (EP)
Number of subjects: 40
Study 33734299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation (enoxaparin, 1 mg/kg daily)
Number of subjects: 600
Study 33734299 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation (enoxaparin, 40 mg daily)
Number of subjects: 600
Study 33734299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 600
Study 33734299 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 600
Study 32061571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular denture with resilient denture liner (RD)
Number of subjects: 0
Study 32061571 — intervention group
Group type: COMPARATOR
Intervention: Mandibular conventional denture (CD)
Number of subjects: 0
Study 34964363 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered self-management program (once a week for 4 weeks)
Number of subjects: 76
Study 33569708 — intervention group
Group type: EXPERIMENTAL
Intervention: Shōchū with catechin‐rich green tea (SC)
Number of subjects: 10
Study 33569708 — intervention group
Group type: COMPARATOR
Intervention: Shōchū with water (SW)
Number of subjects: 10
Study 35736193 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal fish oil diet preconception
Number of subjects: 0
Study 35736193 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0
Study 35736193 — intervention group
Group type: COMPARATOR
Intervention: Supplemental formula diet
Number of subjects: 0
Study 35736193 — intervention group
Group type: COMPARATOR
Intervention: Strict maternal milk diet
Number of subjects: 0
Study 33326064 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 0
Study 33326064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe (20/10 mg)
Number of subjects: 0
Study 33326064 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Ezetimibe
Number of subjects: 0
Study 33326064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 34552947 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted correction of plasma sodium levels
Number of subjects: 2278
Study 34552947 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2278
Study 32973117 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy alone
Number of subjects: 600
Study 32973117 — intervention group
Group type: COMPARATOR
Intervention: Pelvic lymphadenectomy
Number of subjects: 600
Study 35102380 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe energy restriction (65%-75% of energy requirement) with total meal replacement diet for 4 months followed by 8 months of moderate energy restriction (25%-35% of energy requirement)
Number of subjects: 101
Study 35102380 — intervention group
Group type: COMPARATOR
Intervention: Moderate energy restriction (25%-35% of energy requirement) with a food-based diet for 12 months
Number of subjects: 101
Study 33820424 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme Drug-Eluting Stents (DES)
Number of subjects: 1629
Study 33820424 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 1629
Study 33820424 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme DES
Number of subjects: 1629
Study 33820424 — intervention group
Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 1629
Study 34449295 — intervention group
Group type: EXPERIMENTAL
Intervention: 274 mg/day ADS-5102
Number of subjects: 558
Study 34449295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study 34449295 — intervention group
Group type: EXPERIMENTAL
Intervention: 137 mg/day ADS-5102
Number of subjects: 558
Study 33663047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 33663047 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 35099997 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 0
Study 35099997 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic-dose heparin
Number of subjects: 0
Study 33332648 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cereal hay (lower WSC)
Number of subjects: 42
Study 33332648 — intervention group
Group type: COMPARATOR
Intervention: Oaten hay (high WSC)
Number of subjects: 42
Study 32728819 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic nerve gliding (ND)
Number of subjects: 22
Study 32728819 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (ST)
Number of subjects: 22
Study 35436859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 240
Study 35436859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 240
Study 35436859 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 240
Study 32720916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery scratchy ticket reward for good bowel preparation
Number of subjects: 0
Study 32720916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education session delivered over the phone by a trained nurse
Number of subjects: 0
Study 32720916 — intervention group
Group type: COMPARATOR
Intervention: No additional measure (Control)
Number of subjects: 0
Study 35265981 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulant (NOAC)
Number of subjects: 59076
Study 35265981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 59076
Study 35265981 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59076
Study 36001711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab (150 mg on day 1, followed by 450 mg on day 15 and at weeks 24, 48, and 72)
Number of subjects: 1094
Study 36001711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab
Number of subjects: 1094
Study 36001711 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide (14 mg once daily)
Number of subjects: 1094
Study 36001711 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 1094
Study 34155687 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education programme including five online-learning delirium care videos, one face-to-face education session, and a role-play scenario-based initiative.
Number of subjects: 72
Study 34155687 — intervention group
Group type: COMPARATOR
Intervention: Online videos (same as provided to the intervention group).
Number of subjects: 72
Study 32897129 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcised partners
Number of subjects: 4982
Study 32897129 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised partners
Number of subjects: 4982
Study 34837305 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash (15 ml for 1 min)
Number of subjects: 100
Study 34837305 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 100
Study 34837305 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthwash
Number of subjects: 100
Study 34806471 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescent cholangiography (NIFC) with indocyanine green (ICG)
Number of subjects: 161
Study 34806471 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (control group)
Number of subjects: 161
Study 35433276 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group psychoeducation sessions
Number of subjects: 69
Study 35433276 — intervention group
Group type: EXPERIMENTAL
Intervention: Online progressive muscle relaxation (PMR) group sessions
Number of subjects: 69
Study 35433276 — intervention group
Group type: COMPARATOR
Intervention: No group sessions (control condition)
Number of subjects: 69
Study 35433276 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (including control)
Number of subjects: 69
Study 33755640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride topical anesthetic spray
Number of subjects: 100
Study 33755640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tissue culture grade water)
Number of subjects: 100
Study 32787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention (family, school, and community components, including 6 counseling sessions for families at risk)
Number of subjects: 898
Study 32787943 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 898
Study 34882827 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based ultrasomic analysis
Number of subjects: 324
Study 35168907 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthetics (desflurane, isoflurane, or sevoflurane)
Number of subjects: 5400
Study 34603073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 62
Study 34603073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 62
Study 34603073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 34574438 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer-led community-based intervention
Number of subjects: 21
Study 34574438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 34574438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 21
Study 32471369 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital insertion of Foley catheter
Number of subjects: 86
Study 32471369 — intervention group
Group type: COMPARATOR
Intervention: Speculum insertion of Foley catheter
Number of subjects: 86
Study 36007724 — intervention group
Group type: EXPERIMENTAL
Intervention: CTgRT (Stereotactic Body Radiation Therapy with CT guidance)
Number of subjects: 100
Study 36007724 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgRT (Stereotactic Body Radiation Therapy with MRI guidance)
Number of subjects: 100
Study 33526485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (10 mg/kg) followed by intravenous artesunate (2.4 mg/kg)
Number of subjects: 82
Study 33526485 — intervention group
Group type: COMPARATOR
Intervention: Intravenous artesunate (2.4 mg/kg)
Number of subjects: 82
Study 32327428 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibition (TNFi)
Number of subjects: 2420
Study 35317614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 7 days
Number of subjects: 382
Study 35317614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 32875733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet without any restriction on energy intake
Number of subjects: 50
Study 32875733 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial energy‐restricted ketogenic Mediterranean diet
Number of subjects: 50
Study 32875733 — intervention group
Group type: COMPARATOR
Intervention: Energy‐restricted Mediterranean diet
Number of subjects: 50
Study 36942060 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg daily for four weeks
Number of subjects: 43